Nowak M M, Ponsky J L
J Surg Oncol. 1984 Oct;27(2):124-30. doi: 10.1002/jso.2930270214.
A retrospective study was undertaken to determine the effect of perioperative blood transfusion on disease-free survival rates in patients with carcinoma of the breast. The charts of 81 patients participating in a NSABP breast cancer protocol at The Mt. Sinai Medical Center, Cleveland, Ohio, were reviewed. There was no statistically significant difference in disease-free survival between those patients receiving blood transfusions and those that did not when considering the entire group of patients or subgroups based upon age, nodal status, estrogen receptor status, or progesterone receptor status. However, the subgroup of patients receiving tamoxifen chemotherapy, especially those with positive estrogen receptors, had significantly reduced disease-free survival (P less than .05) when given blood transfusions. These results suggest an adverse effect of blood transfusion on disease-free survival in breast cancer patients treated with tamoxifen chemotherapy.
进行了一项回顾性研究，以确定围手术期输血对乳腺癌患者无病生存率的影响。回顾了俄亥俄州克利夫兰市西奈山医疗中心参与NSABP乳腺癌方案的81例患者的病历。在考虑整个患者组或根据年龄、淋巴结状态、雌激素受体状态或孕激素受体状态划分的亚组时，接受输血的患者与未接受输血的患者之间的无病生存率没有统计学上的显著差异。然而，接受他莫昔芬化疗的患者亚组，尤其是雌激素受体阳性的患者，在接受输血时无病生存率显著降低（P小于0.05）。这些结果表明输血对接受他莫昔芬化疗的乳腺癌患者的无病生存有不利影响。
